News & Events
Today the subscription period in Genetic Analysis subsequent offering begins (opens in a new tab)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS R…
Genetic Analysis first day of trading excluding subscription rights (opens in a new tab)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS R…
Genetic Analysis publishes Simplified disclosure document relating to the previously announced subsequent offering (opens in a new tab)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS R…
Genetic Analysis Last day of trading including subscription rights (opens in a new tab)
Oslo, Norway, June 2, 2025 – Genetic Analysis AS (“GA” or the “Company”) hereby announces that today, the 2[nd] of June, 2025, is the last day of trading including subscription rights in the ongoing Subsequent Issue. Reference is made to the stock exchange announcement published by Genetic Analysis AS on 5 May and 27 M…
Correction: Publication of Q1 report January – March 2025 (opens in a new tab)
Correction due to an incorrect EBITDA figure. In the previously published report, EBITDA was incorrectly stated as NOK -3.5 million for the period January 1, 2025 – March 31, 2025, and NOK -4.5 million for the corresponding quarter in 2024. The correct EBITDA is NOK -3.1 million for the first quarter of 2025, and NOK -…
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting (opens in a new tab)
Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT) CAMBRIDGE, Mass. , May 27, 2025 (GLOBE NEWSWIRE) — Seres Therapeutics, Inc.…
Genetic Analysis announces details of Subsequent Offering following directed issue (opens in a new tab)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS R…
Publication of Q1 report January – March 2025 (opens in a new tab)
OSLO, NORWAY – May 27 2025: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the interim report for the period January 1 – March 31, 2025. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report. Ronny Hermansen, CEO of Genetic Analy…
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates (opens in a new tab)
In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological…
Correction: Genetic Analysis announces placement of a directed share issue of NOK 12.8 million (opens in a new tab)
Correction due to an incorrect date in the preamble regarding the calculation of the subscription price. The date was previously stated as 24 May 2024, but the correct date is 24 April 2025. The rest of the press release remains unchanged. NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNI…
Genetic Analysis announces proposed changes to the Board (opens in a new tab)
The post Genetic Analysis announces proposed changes to the Board appeared first on Genetic Analysis.…
Genetic Analysis announces placement of a directed share issue of NOK 12.8 million (opens in a new tab)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS R…
Genetic Analysis AS publishes Annual Report 2024 (opens in a new tab)
OSLO, NORWAY – 2 May 2025: Genetic Analysis AS (the “Company”, Ticker: GEAN) hereby publishes the Annual Report for the financial year of 2024. The Annual Report is available as an attached file to this release and on the Company’s website (www.genetic-analysis.com).…
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases (opens in a new tab)
CAMBRIDGE, Mass. , April 29, 2025 (GLOBE NEWSWIRE) — Seres Therapeutics , Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference being held May 3-6, 2025 , in San Diego,…
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 (opens in a new tab)
CAMBRIDGE, Mass. , April 23, 2025 (GLOBE NEWSWIRE) — Seres Therapeutics , Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results…
Genetic Analysis AS and Thalys Medical Technology Group are pleased to announce the launch of a microbiome test to the Chinese Consumer Health market (opens in a new tab)
OSLO, NORWAY/SHANGHAI, CHINA – 22. April 2025: Microbiome DX company Genetic Analysis AS (“GA”) and Thalys Medical Technology Group Corporation (“Thalys”) announces the launch of a microbiome test for the Consumer Health (D2C) market in China. The test is based on GA’s clinically validated microbiome test, the GA-map® …
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (opens in a new tab)
Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Company expects to submit draft study protocol to FDA in Q2…
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025 (opens in a new tab)
CAMBRIDGE, Mass. , March 04, 2025 (GLOBE NEWSWIRE) — Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on March 13, 2025 at 8:30 a.m. ET to discuss fourth quarter and full year 2024…
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach (opens in a new tab)
FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) as of 30 days post HSCT in the next study Seres has submitted clarification questions to FDA and…
Genetic Analysis AS publishes year-end report 2024 (opens in a new tab)
OSLO, NORWAY – 26 February 2025: Genetic Analysis AS (the “Company”, Ticker: GEAN) hereby publishes the year-end report for the period 1 January – December 31, 2024. The year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report. Ronny Hermansen, CEO …